ストックスクリーナーアプリを入手
1.12
0.00%
0.00
アフターアワーズ：
1.14
0.02
+1.79%
前日終値:
$1.12
開ける：
$1.14
24時間の取引高:
230.21K
Relative Volume:
0.22
時価総額：
$59.07M
収益：
-
当期純損益:
$-151.16M
株価収益率:
-0.3771
EPS:
-2.97
ネットキャッシュフロー:
$-130.08M
1週間 パフォーマンス:
+1.82%
1か月 パフォーマンス:
-32.12%
6か月 パフォーマンス:
-55.20%
1年 パフォーマンス:
-92.94%
1日の値動き範囲:
$1.10
$1.16
1週間の範囲:
$1.10
$1.22
52週間の値動き範囲:
$0.9626
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
名前
Alx Oncology Holdings Inc
セクター
電話
650-466-7125
住所
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.12 | 59.07M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | アップグレード | Jefferies | Hold → Buy |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-06 | 開始されました | UBS | Buy |
| 2021-02-10 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 開始されました | Credit Suisse | Outperform |
| 2020-08-11 | 開始されました | Jefferies | Buy |
| 2020-08-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Alx Oncology Holdings Inc (ALXO) 最新ニュース
Alx oncology SVP Shelly Pinto sells $632 in common stock By Investing.com - Investing.com Nigeria
Alx oncology president Jaume Pons sells $1,525 in stock - Investing.com India
Alx oncology ceo Jason Lettmann sells shares for $2,483 - Investing.com India
February 2025 US Penny Stocks With Promising Prospects - Yahoo Finance
Evorpacept shows promise in HER2-positive cancer trial - MSN
ALX Oncology to Host Virtual R&D Day on March 5, 2025 - GlobeNewswire
ALX Oncology Reveals Next-Gen Cancer Pipeline: Expert Panel to Unveil Evorpacept Breakthroughs - StockTitan
Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Price Target at $3.05 - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Recent Insider Activity Suggests Potential Gains for Alx Oncology Holdings Inc (ALXO) - Knox Daily
Market Momentum: Alx Oncology Holdings Inc (ALXO) Registers a -9.17 Decrease, Closing at 1.09 - The Dwinnex
An analyst sees good growth prospects for Alx Oncology Holdings Inc (ALXO) - SETE News
Is it possible to buy Alx Oncology Holdings Inc(ALXO) shares at a good price now? - US Post News
Alx Oncology Holdings Inc (ALXO) receives a Hold rating from Jefferies - Knox Daily
Form S-8Securities to be offered to employees in employee benefit plans - br.ADVFN.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 9.4% in January - MarketBeat
ALX Oncology (NASDAQ:ALXO) Price Target Lowered to $2.20 at UBS Group - Defense World
H.C. Wainwright cuts ALX Oncology target to $5, keeps buy rating - MSN
UBS cuts ALX Oncology target to $2.20, keeps Buy rating By Investing.com - Investing.com UK
ALX Oncology (NASDAQ:ALXO) Price Target Cut to $2.20 by Analysts at UBS Group - MarketBeat
ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
Analysts Issue Forecasts for ALX Oncology FY2029 Earnings - MarketBeat
HC Wainwright Comments on ALX Oncology FY2029 Earnings - Defense World
HC Wainwright Has Lowered Expectations for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALX Oncology (NASDAQ:ALXO) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
ALX Oncology says evorpacept scores well in Phase II study - The Pharma Letter
Stifel maintains hold on ALX Oncology shares, keeps $3 target By Investing.com - Investing.com UK
ALX Oncology (NASDAQ:ALXO) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat
Barclays PLC Grows Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Presents Positive Updated Data from ASPEN-06 - GlobeNewswire
Cantor Fitzgerald Forecasts ALX Oncology FY2025 Earnings - MarketBeat
Cantor Fitzgerald Predicts ALX Oncology FY2025 Earnings - Defense World
Evorpacept shows promise in HER2-positive cancer trial By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ALX Oncology Shares Drop 15% Following Positive Phase 2 - GuruFocus.com
ALX Oncology stock falls 16% amid Phase 2 data update - MSN
Cantor Fitzgerald Weighs in on ALX Oncology FY2025 Earnings - MarketBeat
ALX Oncology Holdings Inc. Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer - Marketscreener.com
ALX Oncology (ALXO) Presents Positive Updated Data from ASPEN-06 Phase 2 Trial - StreetInsider.com
ALX Oncology's Evorpacept Shows Breakthrough 49% Response Rate in Gastric Cancer Trial - StockTitan
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times
ALX Oncology Grants 600,000 Stock Options to New CFO Harish Shantharam at $1.65 - StockTitan
ALX Oncology Announces Further Additions to Leadership Team - GlobeNewswire
ALX Oncology Strengthens Leadership with Key Appointments - TipRanks
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - The Manila Times
ALX Oncology Strengthens Leadership with Strategic CFO and Board Appointments for Clinical Push - StockTitan
Alx Oncology Holdings Inc (ALXO) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):